Literature DB >> 1973551

Friend virus replication in normal and immunosuppressed C57BL/6 mice.

H C Van der Gaag1, A A Axelrad.   

Abstract

Young adult C57BL/6 mice are resistant to the replication of Friend virus. We show here that this resistance is not absolute. In 7-week old C57BL/6 mice injected with NB-tropic Friend virus iv, high titers of SFFV could be recovered from the spleen at 8 days after infection but by 21 days, no virus was detectable. A single dose of anti-Thy 1.2 monoclonal antibody iv before FV infection permitted continued replication of SFFV in these animals. This finding strongly supports the hypothesis that SFFV replication in C57BL/6 mice is restricted by a T cell-mediated immune response.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1973551     DOI： 10.1016/0042-6822(90)90561-5

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  11 in total

1.  Mutations in the env gene of friend spleen focus-forming virus overcome Fv-2r-mediated resistance to Friend virus-induced erythroleukemia.

Authors:  M K Majumdar; C L Cho; M T Fox; K L Eckner; S Kozak; D Kabat; R W Geib
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice.

Authors:  K J Hasenkrug
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutation.

Authors:  Karen Rulli; Takashi Yugawa; Charlotte Hanson; Delores Thompson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

7.  A Friend virus mutant that overcomes Fv-2rr host resistance encodes a small glycoprotein that dimerizes, is processed to cell surfaces, and specifically activates erythropoietin receptors.

Authors:  S L Kozak; M E Hoatlin; F E Ferro; M K Majumdar; R W Geib; M T Fox; D Kabat
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

Authors:  Mario L Santiago; Mauricio Montano; Robert Benitez; Ronald J Messer; Wes Yonemoto; Bruce Chesebro; Kim J Hasenkrug; Warner C Greene
Journal:  Science       Date:  2008-09-05       Impact factor: 47.728

10.  Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection.

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; George Kassiotis; Kim J Hasenkrug; Ulf Dittmer; Kathrin Gibbert; Mario L Santiago
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.